Capecitabine Tablet, Film Coated
Product Images NDC 72205-006

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 72205-006). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

150mg-60s (Capcetabine 150mg 60s Count)

150mg-60s (Capcetabine 150mg 60s Count)
Each film-coated tablet contains 60 tablets. The usual dosage should be seen in the package insert. The tablets should be stored at a temperature of 25°C (77°F) with excursions permitted to 15°-30°C (53°-86°F). Also, the tablets should be kept tightly closed and dispensed in light containers as defined in USPNF. They are manufactured by MSN Laboratories Private Limited, in India. The accompanying Patient Information Leaflet should be given to each patient by the pharmacist. For more information, contact Novadoz at 855 - SEES.*
FDA Label Image

500mg-120s (Capcetabine 500mg 120s Count)

500mg-120s (Capcetabine 500mg 120s Count)
This is a description of Capecitabine tablets, USP by Novadoz Pharmaceuticals LLC. Each film-coated tablet contains 500mg of Capecitabine, USP. It is a prescription drug that should be dispensed by a pharmacist and comes with an accompanying patient information leaflet. The recommended dosage and other important prescribing information can be found in the insert. The tablets should be stored at a controlled room temperature and tightly closed in containers defined in USP/INF. It is manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. For more patient information, visit their website at www.NovadozPharma.com/Products.*
FDA Label Image

Fig-01 (Capecitabine Figure 01)

Fig-01 (Capecitabine Figure 01)
This appears to be a table displaying survival rates over time for two different treatment groups, 5FU+LEUCOVORIN and CAPECITABINE. The table includes the number of participants at risk and the number of months since randomization.*
FDA Label Image

Fig-02 (Capecitabine Figure 02)

Fig-02 (Capecitabine Figure 02)
This is a survival chart showing the number of people at risk over time for two treatments: 5FU + LEUCOVORIN and CAPECITABINE. The chart shows the number of people still alive at certain time intervals. The treatment groups are shown at the bottom of the chart.*
FDA Label Image

Fig-03 (Capecitabine Figure 03)

Fig-03 (Capecitabine Figure 03)
FDA Label Image

Fig-4 (Capecitabine Figure 04)

Fig-4 (Capecitabine Figure 04)
FDA Label Image

Fig-5 (Capecitabine Figure 05)

Fig-5 (Capecitabine Figure 05)
This appears to be a table showing estimated probability values for different cancer treatment options with varying dosages and time intervals. The treatments mentioned include Docetaxel and Capecitabine, and the dosage amounts are listed in milligrams/square meter. The time intervals are given in days. However, without further context or explanation, it is difficult to provide more specific information or analysis.*
FDA Label Image

For (Capecitabine Formula)

For (Capecitabine Formula)
FDA Label Image

Stru (Capecitabine Structure)

Stru (Capecitabine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.